Expert Outlook: Sage Therapeutics Through The Eyes Of 14 Analysts
Portfolio Pulse from Benzinga Insights
In the last three months, 14 analysts have provided ratings on Sage Therapeutics (NASDAQ:SAGE), with a mix of bullish, somewhat bullish, indifferent, somewhat bearish, and bearish sentiments. The average 12-month price target has decreased by 18.83% to $16.64. Several analysts have lowered their price targets and ratings, reflecting a cautious outlook on the company's performance.
July 30, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sage Therapeutics has received mixed ratings from 14 analysts over the past three months, with a notable decrease in the average 12-month price target by 18.83% to $16.64. Several analysts have downgraded their ratings and lowered their price targets, indicating a cautious outlook on the company's performance.
The decrease in the average price target and multiple downgrades by analysts suggest a negative short-term outlook for Sage Therapeutics. The cautious sentiment is likely to put downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100